You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site


Go back


The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to age, weight and dose.*

Simple titration for monotherapy in adults 16 years and above1

Starting dose and first 2 weeks:250 mg b.d.
Increase/decrease after 2 weeks:250 mg b.d.
Maximum recommended dose:1500 mg b.d.

Simple dosing for adjunctive therapy in adults 18 years and above, and from 12–17 years above 50 kg1

Therapeutic starting dose:500 mg b.d.
Increase/decrease after 2–4 weeks:500 mg b.d.
Maximum recommended dose:1500 mg b.d.

* A 750 mg loading dose is recommended on the first day of treatment with Keppra.
Following dialysis, a 250 mg to 500 mg supplemental dose is recommended.

4–6 years old

The tablet formulation is not adapted for use in children under the age of 6 years. Levetiracetam oral solution is the preferred formulation for use in this population. In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg. In all of the above cases, levetiracetam oral solution should be used. 

The safety and efficacy of levetiracetam concentrate for solution for infusion in infants and children less than 4 years have not been established.

Children aged ≥6 years

The initial therapeutic dose is 10 mg/kg twice daily. Depending upon the clinical response and tolerability, the dose can be increased up to 30 mg/kg twice daily. Dose changes should not exceed increases or decreases of 10 mg/kg twice daily every 2 weeks. The lowest effective dose should be used.

Children weighing ≥50 kg

Dose in children 50 kg or greater is the same as in adults.**


**For dose adjustment in renally impaired children above 4 years, please refer to full Prescribing Information.

Read more about Keppra


AED: anti-epileptic drug; b.d.: twice daily.


  1. Levetiracetam. Non Central Data Sheet Version Number: 10. Version Date: 6 January, 2020.

GSK shall not be liable for any damages, claims, liabilities, costs or obligations arising from the use or misuse of information provided herein. 
For safety information on GSK products or to report an Adverse Event, please contact the toll free line 
0800 CALL GSK (0800 2255 475) or email 
Full prescribing information is available on request on
Please note that it may take up to 10 days to process your request. If you need further assistance contact 
GSK House, 1 Industrial Avenue llupeju, Lagos or via email at
GlaxoSmithKline Pharmaceutical Nigeria Ltd, 1 Industrial Avenue, llupeju, Lagos 234-1-271 1000 
©2020 GSK group of companies or its licensor 
Trade marks are owned by or licensed to the GSK group of companies

Keppra is a registered trademark of the GlaxoSmithKline group of companies

PM-NG-LVT-WCNT-200004 Date of preparation: November 2020.